Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Community Health Services | 10 | 2018 | 656 | 1.400 |
Why?
|
Haiti | 28 | 2022 | 550 | 1.310 |
Why?
|
HIV Infections | 38 | 2018 | 17328 | 1.150 |
Why?
|
Tuberculosis, Multidrug-Resistant | 17 | 2023 | 931 | 0.980 |
Why?
|
Lesotho | 10 | 2024 | 74 | 0.960 |
Why?
|
International Cooperation | 8 | 2020 | 1428 | 0.910 |
Why?
|
Rural Population | 15 | 2022 | 2279 | 0.890 |
Why?
|
Antitubercular Agents | 16 | 2023 | 1374 | 0.860 |
Why?
|
Fluorine Radioisotopes | 9 | 1999 | 418 | 0.790 |
Why?
|
Public Policy | 2 | 2022 | 559 | 0.720 |
Why?
|
Resource Allocation | 2 | 2020 | 350 | 0.710 |
Why?
|
Health Planning Organizations | 1 | 2019 | 13 | 0.670 |
Why?
|
Leiomyoma | 2 | 2022 | 636 | 0.660 |
Why?
|
Medical Assistance | 1 | 2020 | 108 | 0.660 |
Why?
|
Organizational Objectives | 2 | 2019 | 426 | 0.630 |
Why?
|
Monoamine Oxidase Inhibitors | 4 | 1999 | 156 | 0.620 |
Why?
|
Delivery of Health Care | 10 | 2023 | 5332 | 0.620 |
Why?
|
Social Support | 8 | 2016 | 2167 | 0.620 |
Why?
|
Monoamine Oxidase | 4 | 1999 | 180 | 0.610 |
Why?
|
Anti-HIV Agents | 13 | 2018 | 4518 | 0.610 |
Why?
|
Health Services Accessibility | 13 | 2022 | 5421 | 0.600 |
Why?
|
Refugees | 3 | 2022 | 595 | 0.600 |
Why?
|
Directly Observed Therapy | 8 | 2018 | 139 | 0.590 |
Why?
|
Developing Countries | 14 | 2020 | 2882 | 0.590 |
Why?
|
Health Plan Implementation | 2 | 2021 | 337 | 0.580 |
Why?
|
Primary Health Care | 5 | 2024 | 4674 | 0.560 |
Why?
|
Population Growth | 1 | 2016 | 50 | 0.550 |
Why?
|
Tuberculosis, Pulmonary | 6 | 2014 | 831 | 0.530 |
Why?
|
Qualitative Research | 6 | 2024 | 3008 | 0.530 |
Why?
|
Birth Rate | 1 | 2016 | 168 | 0.500 |
Why?
|
Rural Health | 3 | 2006 | 296 | 0.490 |
Why?
|
Child Mortality | 3 | 2014 | 205 | 0.490 |
Why?
|
Human Rights | 4 | 2022 | 308 | 0.480 |
Why?
|
Hemorrhagic Fever, Ebola | 2 | 2016 | 420 | 0.480 |
Why?
|
Maternal Health Services | 2 | 2024 | 460 | 0.440 |
Why?
|
Tomography, Emission-Computed | 11 | 1999 | 1122 | 0.430 |
Why?
|
Communicable Disease Control | 5 | 2020 | 848 | 0.420 |
Why?
|
Community Health Planning | 1 | 2013 | 164 | 0.420 |
Why?
|
Caregivers | 4 | 2015 | 2232 | 0.400 |
Why?
|
Receptors, Dopamine D2 | 5 | 1999 | 485 | 0.400 |
Why?
|
Maternal Welfare | 1 | 2012 | 112 | 0.390 |
Why?
|
Uterine Neoplasms | 1 | 2021 | 1420 | 0.390 |
Why?
|
Anti-Retroviral Agents | 5 | 2012 | 1781 | 0.390 |
Why?
|
Health Priorities | 3 | 2020 | 374 | 0.380 |
Why?
|
Medication Adherence | 4 | 2018 | 2166 | 0.370 |
Why?
|
Clinical Trials, Phase IV as Topic | 1 | 2010 | 29 | 0.360 |
Why?
|
Women's Rights | 1 | 2011 | 65 | 0.360 |
Why?
|
Fluoxetine | 3 | 1999 | 733 | 0.350 |
Why?
|
Attitude of Health Personnel | 1 | 2024 | 3880 | 0.350 |
Why?
|
Poverty Areas | 3 | 2006 | 264 | 0.350 |
Why?
|
Sierra Leone | 4 | 2024 | 169 | 0.340 |
Why?
|
HIV | 3 | 2013 | 1582 | 0.340 |
Why?
|
Rural Health Services | 6 | 2014 | 382 | 0.340 |
Why?
|
Infectious Disease Transmission, Vertical | 3 | 2011 | 1351 | 0.330 |
Why?
|
Public Health | 1 | 2022 | 2665 | 0.310 |
Why?
|
Civil Disorders | 1 | 2008 | 8 | 0.310 |
Why?
|
HIV Seropositivity | 4 | 2014 | 960 | 0.300 |
Why?
|
Harm Reduction | 1 | 2009 | 144 | 0.290 |
Why?
|
Humans | 112 | 2024 | 760437 | 0.290 |
Why?
|
Reproductive Medicine | 1 | 2009 | 99 | 0.290 |
Why?
|
Acquired Immunodeficiency Syndrome | 4 | 2010 | 2199 | 0.290 |
Why?
|
Poverty | 10 | 2021 | 2694 | 0.280 |
Why?
|
Blood Specimen Collection | 1 | 2008 | 238 | 0.280 |
Why?
|
Antiretroviral Therapy, Highly Active | 10 | 2012 | 1896 | 0.280 |
Why?
|
Rwanda | 9 | 2018 | 665 | 0.270 |
Why?
|
Narration | 1 | 2008 | 219 | 0.270 |
Why?
|
Tuberculosis | 6 | 2023 | 2012 | 0.260 |
Why?
|
Politics | 2 | 2024 | 814 | 0.260 |
Why?
|
Adolescent Behavior | 2 | 2015 | 1186 | 0.250 |
Why?
|
Family | 4 | 2015 | 3189 | 0.250 |
Why?
|
Pyrrolidines | 2 | 1999 | 338 | 0.250 |
Why?
|
Government Programs | 3 | 2019 | 279 | 0.250 |
Why?
|
Antidepressive Agents, Second-Generation | 2 | 1999 | 489 | 0.250 |
Why?
|
Cajanus | 1 | 2024 | 2 | 0.240 |
Why?
|
Acidosis, Lactic | 1 | 2006 | 145 | 0.240 |
Why?
|
RNA, Plant | 1 | 2024 | 30 | 0.240 |
Why?
|
Health Facilities | 2 | 2022 | 580 | 0.230 |
Why?
|
Health Care Reform | 2 | 2024 | 1245 | 0.230 |
Why?
|
World Health Organization | 3 | 2022 | 1315 | 0.230 |
Why?
|
Family Characteristics | 1 | 2009 | 1000 | 0.230 |
Why?
|
Pregnancy Complications, Infectious | 3 | 2011 | 2151 | 0.220 |
Why?
|
Hypertension | 1 | 2024 | 8527 | 0.220 |
Why?
|
Medical Records Systems, Computerized | 3 | 2004 | 1191 | 0.220 |
Why?
|
Gram-Positive Bacteria | 1 | 2004 | 178 | 0.220 |
Why?
|
Receptors, Dopamine D1 | 2 | 1996 | 293 | 0.220 |
Why?
|
Gene Expression Regulation, Plant | 1 | 2024 | 211 | 0.220 |
Why?
|
Drug Approval | 1 | 2010 | 811 | 0.220 |
Why?
|
Emigrants and Immigrants | 1 | 2009 | 543 | 0.210 |
Why?
|
Clorgyline | 2 | 1999 | 14 | 0.210 |
Why?
|
Benzazepines | 2 | 1996 | 310 | 0.210 |
Why?
|
Chlamydia Infections | 1 | 2006 | 365 | 0.210 |
Why?
|
Vulnerable Populations | 3 | 2017 | 700 | 0.200 |
Why?
|
Violence | 1 | 2008 | 936 | 0.200 |
Why?
|
Depressive Disorder | 2 | 2017 | 3728 | 0.200 |
Why?
|
Organizational Case Studies | 3 | 2020 | 301 | 0.200 |
Why?
|
Gonorrhea | 1 | 2006 | 346 | 0.200 |
Why?
|
Social Stigma | 3 | 2014 | 768 | 0.190 |
Why?
|
Sexual Partners | 4 | 2010 | 795 | 0.190 |
Why?
|
Benzamides | 2 | 1999 | 1370 | 0.190 |
Why?
|
Women's Health | 1 | 2011 | 2065 | 0.190 |
Why?
|
Medically Underserved Area | 1 | 2003 | 256 | 0.190 |
Why?
|
Rats, Sprague-Dawley | 12 | 1999 | 8163 | 0.190 |
Why?
|
Patient Compliance | 4 | 2012 | 2689 | 0.180 |
Why?
|
National Health Programs | 2 | 2019 | 440 | 0.180 |
Why?
|
Health Resources | 2 | 2003 | 935 | 0.170 |
Why?
|
Interviews as Topic | 3 | 2024 | 2683 | 0.170 |
Why?
|
Dextroamphetamine | 2 | 1997 | 134 | 0.170 |
Why?
|
Female | 49 | 2024 | 391875 | 0.170 |
Why?
|
Students | 1 | 2009 | 1739 | 0.170 |
Why?
|
Malawi | 4 | 2023 | 304 | 0.170 |
Why?
|
Depression | 5 | 2017 | 8104 | 0.170 |
Why?
|
Radiopharmaceuticals | 2 | 1999 | 2646 | 0.160 |
Why?
|
Health Promotion | 2 | 2011 | 2211 | 0.160 |
Why?
|
Quality of Life | 1 | 2021 | 13338 | 0.160 |
Why?
|
Maternal Mortality | 2 | 2012 | 301 | 0.160 |
Why?
|
Financing, Organized | 1 | 2020 | 204 | 0.160 |
Why?
|
Health Services Administration | 2 | 2017 | 63 | 0.160 |
Why?
|
Uridine Monophosphate | 1 | 2018 | 68 | 0.150 |
Why?
|
Disease Outbreaks | 4 | 2022 | 1762 | 0.150 |
Why?
|
Earthquakes | 1 | 2021 | 190 | 0.150 |
Why?
|
Propylamines | 1 | 1999 | 161 | 0.150 |
Why?
|
Peru | 6 | 2008 | 890 | 0.150 |
Why?
|
Health Services Needs and Demand | 2 | 2016 | 1403 | 0.150 |
Why?
|
Extensively Drug-Resistant Tuberculosis | 2 | 2008 | 85 | 0.150 |
Why?
|
Health Policy | 5 | 2014 | 2680 | 0.150 |
Why?
|
Fluorenes | 1 | 2018 | 157 | 0.150 |
Why?
|
Consumer Advocacy | 2 | 2011 | 81 | 0.150 |
Why?
|
Socioeconomic Factors | 3 | 2010 | 7817 | 0.140 |
Why?
|
Medical Informatics | 1 | 2004 | 733 | 0.140 |
Why?
|
Parents | 2 | 2015 | 3563 | 0.140 |
Why?
|
Pregnancy | 9 | 2024 | 29831 | 0.140 |
Why?
|
Point-of-Care Systems | 1 | 2006 | 1212 | 0.140 |
Why?
|
House Calls | 1 | 2018 | 161 | 0.140 |
Why?
|
Social Responsibility | 1 | 2020 | 386 | 0.140 |
Why?
|
Health Personnel | 4 | 2024 | 3331 | 0.140 |
Why?
|
Brain | 10 | 1999 | 27060 | 0.140 |
Why?
|
Drug Costs | 2 | 2004 | 1179 | 0.140 |
Why?
|
Liberia | 1 | 2016 | 174 | 0.130 |
Why?
|
Salicylamides | 1 | 1996 | 33 | 0.130 |
Why?
|
Male | 46 | 2024 | 360035 | 0.130 |
Why?
|
Program Development | 3 | 2014 | 1297 | 0.130 |
Why?
|
Rats | 12 | 1999 | 23712 | 0.130 |
Why?
|
Education, Medical, Graduate | 2 | 2021 | 2367 | 0.130 |
Why?
|
Adult | 30 | 2024 | 220781 | 0.130 |
Why?
|
Pandemics | 4 | 2022 | 8623 | 0.130 |
Why?
|
Fees and Charges | 1 | 2016 | 192 | 0.130 |
Why?
|
Program Evaluation | 7 | 2018 | 2493 | 0.130 |
Why?
|
Financing, Government | 1 | 2019 | 472 | 0.130 |
Why?
|
Rape | 2 | 2007 | 131 | 0.120 |
Why?
|
Antiviral Agents | 2 | 2018 | 3066 | 0.120 |
Why?
|
United Nations | 3 | 2011 | 150 | 0.120 |
Why?
|
Parent-Child Relations | 2 | 2010 | 760 | 0.120 |
Why?
|
Binding, Competitive | 4 | 1998 | 1141 | 0.120 |
Why?
|
Education, Nursing, Diploma Programs | 1 | 2014 | 11 | 0.120 |
Why?
|
Radioligand Assay | 4 | 1999 | 366 | 0.120 |
Why?
|
Malnutrition | 1 | 2021 | 644 | 0.120 |
Why?
|
Population Dynamics | 1 | 2016 | 307 | 0.120 |
Why?
|
Social Medicine | 1 | 2015 | 64 | 0.120 |
Why?
|
Drug Resistance, Multiple | 2 | 2007 | 257 | 0.120 |
Why?
|
Tissue Distribution | 5 | 1999 | 2265 | 0.120 |
Why?
|
Macaca mulatta | 7 | 1999 | 2322 | 0.120 |
Why?
|
Mali | 1 | 2013 | 50 | 0.110 |
Why?
|
Cross-Sectional Studies | 7 | 2023 | 26063 | 0.110 |
Why?
|
Autoradiography | 3 | 1999 | 730 | 0.110 |
Why?
|
Ebolavirus | 1 | 2016 | 251 | 0.110 |
Why?
|
Retrospective Studies | 18 | 2024 | 80430 | 0.110 |
Why?
|
Critical Illness | 2 | 2023 | 2722 | 0.110 |
Why?
|
Adaptation, Psychological | 3 | 2015 | 2629 | 0.110 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2016 | 394 | 0.110 |
Why?
|
Quality Improvement | 2 | 2023 | 3798 | 0.110 |
Why?
|
Public-Private Sector Partnerships | 1 | 2014 | 122 | 0.110 |
Why?
|
Corpus Striatum | 2 | 1999 | 1235 | 0.110 |
Why?
|
Benzimidazoles | 1 | 2018 | 855 | 0.110 |
Why?
|
Learning | 1 | 2022 | 1740 | 0.110 |
Why?
|
Internal-External Control | 1 | 2015 | 359 | 0.110 |
Why?
|
Intensive Care Units | 2 | 2023 | 3742 | 0.110 |
Why?
|
Hospitals | 2 | 2023 | 3873 | 0.110 |
Why?
|
Nurse Midwives | 1 | 2012 | 23 | 0.100 |
Why?
|
Uganda | 2 | 2008 | 1332 | 0.100 |
Why?
|
Health Services Research | 2 | 2017 | 1811 | 0.100 |
Why?
|
Education, Nursing | 1 | 2012 | 80 | 0.100 |
Why?
|
Personnel, Hospital | 1 | 2014 | 285 | 0.100 |
Why?
|
HIV Seronegativity | 2 | 2010 | 211 | 0.100 |
Why?
|
Glycemic Index | 1 | 2014 | 395 | 0.100 |
Why?
|
Inservice Training | 1 | 2014 | 375 | 0.100 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2009 | 4569 | 0.100 |
Why?
|
Child, Orphaned | 1 | 2012 | 55 | 0.100 |
Why?
|
Comprehensive Health Care | 1 | 2012 | 123 | 0.090 |
Why?
|
Healthy People Programs | 1 | 2011 | 54 | 0.090 |
Why?
|
Midwifery | 1 | 2012 | 123 | 0.090 |
Why?
|
Mother-Child Relations | 1 | 2014 | 494 | 0.090 |
Why?
|
Epidemics | 1 | 2016 | 512 | 0.090 |
Why?
|
Truth Disclosure | 1 | 2014 | 433 | 0.090 |
Why?
|
Self-Help Groups | 1 | 2012 | 189 | 0.090 |
Why?
|
Viral Load | 6 | 2018 | 3329 | 0.090 |
Why?
|
Therapeutic Human Experimentation | 1 | 2010 | 43 | 0.090 |
Why?
|
Curriculum | 2 | 2021 | 3732 | 0.090 |
Why?
|
Hepatitis C, Chronic | 1 | 2018 | 1032 | 0.090 |
Why?
|
Child, Preschool | 8 | 2022 | 42209 | 0.090 |
Why?
|
Child Development | 1 | 2022 | 2302 | 0.090 |
Why?
|
Occupations | 2 | 2010 | 515 | 0.090 |
Why?
|
Research Design | 1 | 2006 | 6168 | 0.090 |
Why?
|
Russia | 5 | 2008 | 383 | 0.080 |
Why?
|
Adolescent | 15 | 2017 | 88196 | 0.080 |
Why?
|
Risk Factors | 8 | 2021 | 74055 | 0.080 |
Why?
|
Child Welfare | 1 | 2013 | 519 | 0.080 |
Why?
|
Infant | 6 | 2022 | 36183 | 0.080 |
Why?
|
Drug Resistance, Multiple, Bacterial | 2 | 2004 | 587 | 0.080 |
Why?
|
RNA, Messenger | 1 | 2024 | 12785 | 0.080 |
Why?
|
Treatment Outcome | 14 | 2018 | 64591 | 0.080 |
Why?
|
Meningitis | 1 | 2010 | 218 | 0.080 |
Why?
|
CD4 Lymphocyte Count | 5 | 2018 | 2569 | 0.080 |
Why?
|
Africa | 2 | 2016 | 709 | 0.080 |
Why?
|
Healthcare Disparities | 3 | 2021 | 3344 | 0.080 |
Why?
|
Prevalence | 4 | 2021 | 15698 | 0.080 |
Why?
|
Schools, Medical | 1 | 2015 | 878 | 0.080 |
Why?
|
Pilot Projects | 4 | 2015 | 8611 | 0.080 |
Why?
|
Patient Dropouts | 2 | 2012 | 412 | 0.080 |
Why?
|
Mexico | 2 | 2023 | 761 | 0.080 |
Why?
|
Fluoroquinolones | 1 | 2010 | 308 | 0.080 |
Why?
|
Communicable Diseases | 1 | 2016 | 879 | 0.080 |
Why?
|
Psychology | 1 | 2010 | 356 | 0.070 |
Why?
|
MicroRNAs | 1 | 2024 | 3796 | 0.070 |
Why?
|
Skull | 1 | 1992 | 818 | 0.070 |
Why?
|
Social Conditions | 1 | 2008 | 119 | 0.070 |
Why?
|
Clinical Trials as Topic | 1 | 2003 | 7996 | 0.070 |
Why?
|
Nigeria | 1 | 2010 | 770 | 0.070 |
Why?
|
Mentors | 1 | 2012 | 660 | 0.070 |
Why?
|
Psychometrics | 1 | 2017 | 3063 | 0.070 |
Why?
|
Telemedicine | 1 | 2024 | 3027 | 0.070 |
Why?
|
Multicenter Studies as Topic | 1 | 2012 | 1703 | 0.070 |
Why?
|
Hepatitis C | 1 | 2017 | 1583 | 0.070 |
Why?
|
Disease Management | 1 | 2017 | 2501 | 0.070 |
Why?
|
Child | 11 | 2022 | 80086 | 0.070 |
Why?
|
Health Status | 1 | 2020 | 4071 | 0.070 |
Why?
|
Liver Cirrhosis | 1 | 2017 | 1934 | 0.070 |
Why?
|
Fellowships and Scholarships | 1 | 2015 | 1117 | 0.070 |
Why?
|
HIV-1 | 5 | 2010 | 6859 | 0.070 |
Why?
|
Boston | 3 | 2009 | 9326 | 0.070 |
Why?
|
Research Support as Topic | 1 | 2010 | 697 | 0.070 |
Why?
|
Dopamine Antagonists | 2 | 1997 | 288 | 0.060 |
Why?
|
Anti-Bacterial Agents | 1 | 2004 | 7424 | 0.060 |
Why?
|
Goals | 1 | 2011 | 711 | 0.060 |
Why?
|
Obstetrics | 1 | 2012 | 665 | 0.060 |
Why?
|
Algorithms | 1 | 2006 | 14002 | 0.060 |
Why?
|
Conflict of Interest | 1 | 2010 | 554 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2023 | 5835 | 0.060 |
Why?
|
Delivery, Obstetric | 1 | 2012 | 940 | 0.060 |
Why?
|
Haloperidol | 2 | 1997 | 389 | 0.060 |
Why?
|
Capacity Building | 2 | 2020 | 258 | 0.060 |
Why?
|
Marine Biology | 1 | 2004 | 18 | 0.060 |
Why?
|
Prenatal Care | 1 | 2012 | 1134 | 0.060 |
Why?
|
Cholera | 1 | 2011 | 747 | 0.060 |
Why?
|
Health Services | 1 | 2010 | 752 | 0.060 |
Why?
|
Fetus | 1 | 1992 | 1863 | 0.060 |
Why?
|
Organizations | 2 | 2016 | 171 | 0.060 |
Why?
|
Counseling | 2 | 2010 | 1545 | 0.060 |
Why?
|
Reproductive Techniques, Assisted | 1 | 2009 | 497 | 0.060 |
Why?
|
Retreatment | 1 | 2006 | 598 | 0.060 |
Why?
|
Fertility | 1 | 2009 | 771 | 0.060 |
Why?
|
Residence Characteristics | 2 | 2015 | 2087 | 0.060 |
Why?
|
Mothers | 1 | 2014 | 2191 | 0.060 |
Why?
|
Seawater | 1 | 2004 | 124 | 0.060 |
Why?
|
Professional Role | 1 | 2007 | 312 | 0.060 |
Why?
|
Netherlands | 1 | 2008 | 2218 | 0.060 |
Why?
|
General Surgery | 1 | 2015 | 1687 | 0.060 |
Why?
|
Drug Industry | 1 | 2010 | 788 | 0.060 |
Why?
|
Informed Consent | 1 | 2010 | 1006 | 0.060 |
Why?
|
Cardiomyopathies | 1 | 2016 | 1957 | 0.060 |
Why?
|
Thailand | 1 | 2004 | 288 | 0.060 |
Why?
|
Focus Groups | 2 | 2023 | 1404 | 0.060 |
Why?
|
Drug Therapy, Combination | 4 | 2008 | 6297 | 0.060 |
Why?
|
Disease Transmission, Infectious | 1 | 2009 | 557 | 0.050 |
Why?
|
Antibiotics, Antitubercular | 1 | 2004 | 99 | 0.050 |
Why?
|
Patient Rights | 1 | 2004 | 125 | 0.050 |
Why?
|
Education, Medical | 1 | 2015 | 1726 | 0.050 |
Why?
|
Risk-Taking | 1 | 2009 | 1036 | 0.050 |
Why?
|
Survival Analysis | 2 | 2017 | 10075 | 0.050 |
Why?
|
Social Change | 1 | 2003 | 153 | 0.050 |
Why?
|
Anti-Infective Agents | 1 | 2010 | 984 | 0.050 |
Why?
|
Infant, Newborn | 4 | 2011 | 26280 | 0.050 |
Why?
|
Weight Loss | 1 | 2014 | 2683 | 0.050 |
Why?
|
Prisoners | 1 | 2006 | 314 | 0.050 |
Why?
|
Patient Acceptance of Health Care | 1 | 2016 | 3190 | 0.050 |
Why?
|
Social Environment | 1 | 2007 | 1020 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3080 | 0.050 |
Why?
|
Middle Aged | 15 | 2021 | 220382 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3200 | 0.050 |
Why?
|
Interpersonal Relations | 1 | 2009 | 1436 | 0.050 |
Why?
|
Anthropology, Cultural | 1 | 2022 | 102 | 0.050 |
Why?
|
Linear Models | 1 | 2012 | 5865 | 0.050 |
Why?
|
Students, Medical | 1 | 2015 | 1930 | 0.050 |
Why?
|
Africa South of the Sahara | 1 | 2024 | 743 | 0.050 |
Why?
|
Civil Rights | 1 | 2022 | 132 | 0.050 |
Why?
|
Pregnancy Outcome | 1 | 2012 | 2916 | 0.050 |
Why?
|
Drug Tolerance | 1 | 2003 | 367 | 0.050 |
Why?
|
Antipsychotic Agents | 1 | 1995 | 3066 | 0.050 |
Why?
|
Jordan | 1 | 2021 | 73 | 0.050 |
Why?
|
Drug Resistance, Microbial | 1 | 2004 | 857 | 0.050 |
Why?
|
Breast Feeding | 1 | 2009 | 1357 | 0.050 |
Why?
|
Logistic Models | 3 | 2012 | 13240 | 0.050 |
Why?
|
Young Adult | 8 | 2017 | 59068 | 0.050 |
Why?
|
Animals | 14 | 1999 | 168253 | 0.050 |
Why?
|
Commerce | 1 | 2006 | 604 | 0.050 |
Why?
|
Middle East | 1 | 2021 | 231 | 0.050 |
Why?
|
Hepacivirus | 2 | 2018 | 1337 | 0.050 |
Why?
|
Critical Care | 2 | 2023 | 2697 | 0.040 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2004 | 1037 | 0.040 |
Why?
|
Pediatrics | 1 | 2015 | 3593 | 0.040 |
Why?
|
Kinetics | 2 | 1999 | 6377 | 0.040 |
Why?
|
Selegiline | 1 | 1999 | 32 | 0.040 |
Why?
|
Information Systems | 1 | 2002 | 396 | 0.040 |
Why?
|
RNA, Viral | 3 | 2018 | 2846 | 0.040 |
Why?
|
Follow-Up Studies | 3 | 2016 | 39078 | 0.040 |
Why?
|
DNA, Bacterial | 1 | 2004 | 1481 | 0.040 |
Why?
|
Anxiety | 2 | 2015 | 4558 | 0.040 |
Why?
|
Congresses as Topic | 1 | 2004 | 802 | 0.040 |
Why?
|
Drug Resistance, Viral | 1 | 2004 | 861 | 0.040 |
Why?
|
Canada | 1 | 2004 | 2119 | 0.040 |
Why?
|
Receptors, Dopamine D3 | 1 | 1999 | 108 | 0.040 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2007 | 936 | 0.040 |
Why?
|
Synaptosomes | 1 | 1998 | 116 | 0.040 |
Why?
|
Chronic Disease | 2 | 2012 | 9309 | 0.040 |
Why?
|
Clinical Protocols | 1 | 2004 | 1438 | 0.040 |
Why?
|
Culture Techniques | 1 | 1998 | 531 | 0.040 |
Why?
|
Costs and Cost Analysis | 1 | 2003 | 1668 | 0.040 |
Why?
|
Subcellular Fractions | 1 | 1998 | 532 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2008 | 5236 | 0.040 |
Why?
|
Patients | 1 | 2023 | 905 | 0.040 |
Why?
|
Aspartate Aminotransferases | 1 | 2018 | 417 | 0.040 |
Why?
|
AIDS Vaccines | 1 | 2003 | 896 | 0.040 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2001 | 1766 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2017 | 14661 | 0.030 |
Why?
|
Phylogeny | 1 | 2004 | 2806 | 0.030 |
Why?
|
Cohort Studies | 6 | 2014 | 41366 | 0.030 |
Why?
|
Regression Analysis | 1 | 2006 | 6340 | 0.030 |
Why?
|
Phencyclidine | 1 | 1996 | 60 | 0.030 |
Why?
|
Injections, Intravenous | 1 | 1998 | 1379 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2022 | 22097 | 0.030 |
Why?
|
Macaca | 1 | 1997 | 409 | 0.030 |
Why?
|
Travel | 1 | 2022 | 795 | 0.030 |
Why?
|
Staphylococcus aureus | 1 | 2004 | 1459 | 0.030 |
Why?
|
Alanine Transaminase | 1 | 2018 | 606 | 0.030 |
Why?
|
Raclopride | 1 | 1996 | 101 | 0.030 |
Why?
|
Hospitalization | 1 | 2016 | 10698 | 0.030 |
Why?
|
Cebus | 1 | 1995 | 16 | 0.030 |
Why?
|
Receptors, Serotonin | 1 | 1996 | 208 | 0.030 |
Why?
|
Data Collection | 1 | 2004 | 3321 | 0.030 |
Why?
|
Radioactive Tracers | 1 | 1995 | 66 | 0.030 |
Why?
|
Internet | 2 | 2004 | 3092 | 0.030 |
Why?
|
Brain Chemistry | 1 | 1998 | 959 | 0.030 |
Why?
|
Immunity, Cellular | 1 | 2001 | 1559 | 0.030 |
Why?
|
Disasters | 1 | 2021 | 518 | 0.030 |
Why?
|
History, 21st Century | 1 | 2021 | 1567 | 0.030 |
Why?
|
Carbon Radioisotopes | 1 | 1996 | 562 | 0.030 |
Why?
|
Electric Injuries | 1 | 1994 | 24 | 0.030 |
Why?
|
Needlestick Injuries | 1 | 1994 | 71 | 0.030 |
Why?
|
Mycobacterium tuberculosis | 4 | 2008 | 1912 | 0.030 |
Why?
|
Fluconazole | 1 | 1994 | 156 | 0.030 |
Why?
|
Molecular Structure | 2 | 1996 | 1875 | 0.030 |
Why?
|
Health Education | 1 | 2020 | 1052 | 0.030 |
Why?
|
Government Agencies | 1 | 2014 | 160 | 0.030 |
Why?
|
Cryptococcosis | 1 | 1994 | 104 | 0.030 |
Why?
|
Time Factors | 4 | 2013 | 39947 | 0.030 |
Why?
|
Organ Specificity | 1 | 1998 | 1956 | 0.030 |
Why?
|
Accidents | 1 | 1994 | 165 | 0.030 |
Why?
|
Aged | 10 | 2018 | 168840 | 0.030 |
Why?
|
Hospitals, Rural | 1 | 2015 | 174 | 0.030 |
Why?
|
Viral Proteins | 1 | 2001 | 1803 | 0.030 |
Why?
|
Nepal | 1 | 2014 | 304 | 0.030 |
Why?
|
Teaching | 1 | 2021 | 1169 | 0.030 |
Why?
|
Sputum | 2 | 2008 | 506 | 0.030 |
Why?
|
Structure-Activity Relationship | 2 | 1996 | 3075 | 0.030 |
Why?
|
Sulfonylurea Compounds | 1 | 2014 | 219 | 0.030 |
Why?
|
HIV Seroprevalence | 1 | 2012 | 89 | 0.030 |
Why?
|
Calcium Channels | 1 | 1996 | 620 | 0.030 |
Why?
|
Ligands | 1 | 1999 | 3270 | 0.020 |
Why?
|
Incidence | 2 | 2011 | 21322 | 0.020 |
Why?
|
Thiazoles | 1 | 1999 | 1513 | 0.020 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2014 | 363 | 0.020 |
Why?
|
Heart Failure | 1 | 2016 | 11653 | 0.020 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 1995 | 1540 | 0.020 |
Why?
|
Transfection | 1 | 1999 | 5776 | 0.020 |
Why?
|
Nursing Staff, Hospital | 1 | 2014 | 348 | 0.020 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 1 | 1996 | 894 | 0.020 |
Why?
|
Twins | 1 | 1992 | 339 | 0.020 |
Why?
|
Fetal Death | 1 | 1992 | 435 | 0.020 |
Why?
|
Inpatients | 1 | 2022 | 2545 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2014 | 12127 | 0.020 |
Why?
|
Health Care Costs | 1 | 2003 | 3240 | 0.020 |
Why?
|
Medical Staff, Hospital | 1 | 2014 | 601 | 0.020 |
Why?
|
Dopamine | 1 | 1997 | 1603 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 1999 | 6525 | 0.020 |
Why?
|
Prospective Studies | 3 | 2022 | 54339 | 0.020 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 1994 | 1066 | 0.020 |
Why?
|
Longitudinal Studies | 3 | 2016 | 14565 | 0.020 |
Why?
|
Cost-Benefit Analysis | 2 | 2017 | 5491 | 0.020 |
Why?
|
Cerebellum | 1 | 1996 | 1500 | 0.020 |
Why?
|
Physician Incentive Plans | 1 | 2009 | 164 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2019 | 1847 | 0.020 |
Why?
|
Social Isolation | 1 | 2010 | 364 | 0.020 |
Why?
|
Mass Screening | 1 | 2023 | 5424 | 0.020 |
Why?
|
Latvia | 1 | 2006 | 14 | 0.020 |
Why?
|
Estonia | 1 | 2006 | 56 | 0.020 |
Why?
|
Philippines | 1 | 2006 | 90 | 0.020 |
Why?
|
Radiography | 1 | 1997 | 6963 | 0.020 |
Why?
|
Microbial Sensitivity Tests | 2 | 2003 | 1952 | 0.020 |
Why?
|
Fear | 1 | 2014 | 1471 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 1997 | 10759 | 0.020 |
Why?
|
United States | 3 | 2021 | 72202 | 0.020 |
Why?
|
Cell Line | 1 | 1999 | 15598 | 0.020 |
Why?
|
Mitochondria | 1 | 1998 | 3624 | 0.020 |
Why?
|
Leadership | 1 | 2014 | 1379 | 0.020 |
Why?
|
Emergency Medical Services | 1 | 2016 | 1918 | 0.020 |
Why?
|
Insurance, Health | 1 | 2017 | 2491 | 0.010 |
Why?
|
Risk Assessment | 1 | 2006 | 23953 | 0.010 |
Why?
|
Diffusion of Innovation | 1 | 2009 | 726 | 0.010 |
Why?
|
Health Expenditures | 1 | 2017 | 2353 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2013 | 6230 | 0.010 |
Why?
|
Epitopes | 2 | 2001 | 2504 | 0.010 |
Why?
|
Genotype | 1 | 2018 | 12976 | 0.010 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2007 | 487 | 0.010 |
Why?
|
Academic Medical Centers | 1 | 2014 | 2757 | 0.010 |
Why?
|
Perception | 1 | 2010 | 1196 | 0.010 |
Why?
|
Body Weight | 1 | 2014 | 4614 | 0.010 |
Why?
|
Risk | 1 | 2015 | 9605 | 0.010 |
Why?
|
Cooperative Behavior | 1 | 2010 | 1504 | 0.010 |
Why?
|
Length of Stay | 1 | 2016 | 6413 | 0.010 |
Why?
|
Hospital Mortality | 1 | 2016 | 5283 | 0.010 |
Why?
|
Information Management | 1 | 2002 | 100 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 1997 | 8967 | 0.010 |
Why?
|
Therapy, Computer-Assisted | 1 | 2003 | 266 | 0.010 |
Why?
|
HLA-A2 Antigen | 1 | 2001 | 211 | 0.010 |
Why?
|
Gene Products, gag | 1 | 2001 | 312 | 0.010 |
Why?
|
HIV Antigens | 1 | 2001 | 325 | 0.010 |
Why?
|
Acute Disease | 2 | 2001 | 7230 | 0.010 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 1 | 2001 | 206 | 0.010 |
Why?
|
Pharmaceutical Preparations | 1 | 2007 | 1087 | 0.010 |
Why?
|
Amino Acid Sequence | 2 | 2001 | 13445 | 0.010 |
Why?
|
Sexually Transmitted Diseases | 1 | 2005 | 662 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2017 | 20078 | 0.010 |
Why?
|
Public Health Practice | 1 | 2001 | 219 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2006 | 4849 | 0.010 |
Why?
|
Comorbidity | 1 | 2012 | 10494 | 0.010 |
Why?
|
Patient-Centered Care | 1 | 2007 | 1416 | 0.010 |
Why?
|
Ambulatory Care | 1 | 2008 | 2771 | 0.010 |
Why?
|
DNA Primers | 1 | 2001 | 2820 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2008 | 8522 | 0.010 |
Why?
|
Dizocilpine Maleate | 1 | 1996 | 172 | 0.010 |
Why?
|
Drug Monitoring | 1 | 2002 | 961 | 0.010 |
Why?
|
Genetic Variation | 2 | 2001 | 6570 | 0.010 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2001 | 973 | 0.010 |
Why?
|
Indicators and Reagents | 1 | 1996 | 462 | 0.010 |
Why?
|
Isotope Labeling | 1 | 1996 | 393 | 0.010 |
Why?
|
Organotechnetium Compounds | 1 | 1994 | 129 | 0.010 |
Why?
|
Research | 1 | 2002 | 1977 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2006 | 12429 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2005 | 12054 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2003 | 3685 | 0.010 |
Why?
|
Base Sequence | 1 | 2001 | 12449 | 0.010 |
Why?
|
Muscles | 1 | 1994 | 1575 | 0.010 |
Why?
|
Smoking | 1 | 2006 | 9046 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2001 | 17639 | 0.000 |
Why?
|
Age Factors | 1 | 2005 | 18379 | 0.000 |
Why?
|
Aged, 80 and over | 1 | 2012 | 58859 | 0.000 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 1996 | 3765 | 0.000 |
Why?
|
Practice Guidelines as Topic | 1 | 2003 | 7380 | 0.000 |
Why?
|